Illumina, Inc. (ILMN) SVP Oene Mark Van Sells 1,250 Shares

Illumina, Inc. (NASDAQ:ILMN) SVP Oene Mark Van sold 1,250 shares of the firm’s stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $207.76, for a total value of $259,700.00. Following the completion of the sale, the senior vice president now directly owns 11,691 shares of the company’s stock, valued at $2,428,922.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Oene Mark Van also recently made the following trade(s):

  • On Monday, November 13th, Oene Mark Van sold 1,232 shares of Illumina stock. The shares were sold at an average price of $207.78, for a total value of $255,984.96.
  • On Thursday, October 12th, Oene Mark Van sold 1,250 shares of Illumina stock. The shares were sold at an average price of $207.21, for a total value of $259,012.50.
  • On Tuesday, September 12th, Oene Mark Van sold 9,729 shares of Illumina stock. The shares were sold at an average price of $211.33, for a total value of $2,056,029.57.

Shares of Illumina, Inc. (NASDAQ:ILMN) traded up $0.51 during mid-day trading on Friday, reaching $209.02. The company’s stock had a trading volume of 545,558 shares, compared to its average volume of 959,780. The company has a debt-to-equity ratio of 0.41, a quick ratio of 3.73 and a current ratio of 4.22. Illumina, Inc. has a 52-week low of $119.37 and a 52-week high of $214.50. The company has a market capitalization of $30,440.00, a price-to-earnings ratio of 60.25, a P/E/G ratio of 3.40 and a beta of 0.74.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.99 by $0.12. Illumina had a return on equity of 19.42% and a net margin of 30.34%. The firm had revenue of $714.00 million during the quarter, compared to analyst estimates of $692.77 million. During the same quarter in the previous year, the company posted $0.97 earnings per share. The company’s revenue was up 17.6% compared to the same quarter last year. equities analysts expect that Illumina, Inc. will post 3.75 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: “Illumina, Inc. (ILMN) SVP Oene Mark Van Sells 1,250 Shares” was originally published by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this news story on another publication, it was stolen and reposted in violation of international trademark and copyright legislation. The correct version of this news story can be read at https://www.truebluetribune.com/2017/11/18/illumina-inc-ilmn-svp-oene-mark-van-sells-1250-shares.html.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ILMN. Winslow Capital Management LLC bought a new stake in shares of Illumina in the 2nd quarter valued at about $211,584,000. HPM Partners LLC lifted its stake in shares of Illumina by 29,103.8% in the 2nd quarter. HPM Partners LLC now owns 751,999 shares of the life sciences company’s stock valued at $107,724,000 after acquiring an additional 749,424 shares during the last quarter. Fred Alger Management Inc. lifted its stake in shares of Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after acquiring an additional 548,030 shares during the last quarter. TIAA CREF Investment Management LLC lifted its stake in shares of Illumina by 55.6% in the 2nd quarter. TIAA CREF Investment Management LLC now owns 1,475,669 shares of the life sciences company’s stock valued at $256,058,000 after acquiring an additional 527,548 shares during the last quarter. Finally, Capital World Investors lifted its stake in shares of Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after acquiring an additional 410,000 shares during the last quarter. 92.70% of the stock is owned by institutional investors.

Several brokerages have recently weighed in on ILMN. BidaskClub cut Illumina from a “hold” rating to a “sell” rating in a research report on Thursday, August 17th. Zacks Investment Research cut Illumina from a “buy” rating to a “hold” rating in a research report on Friday, August 4th. J P Morgan Chase & Co reiterated an “overweight” rating and issued a $250.00 price target on shares of Illumina in a research report on Wednesday, August 2nd. Canaccord Genuity reiterated a “buy” rating and issued a $230.00 price target (up from $215.00) on shares of Illumina in a research report on Thursday, October 12th. Finally, Goldman Sachs Group, Inc. (The) reiterated a “neutral” rating and issued a $200.00 price target on shares of Illumina in a research report on Tuesday, September 26th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and thirteen have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and an average target price of $200.88.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply